pharmacueticals
Competitors, critics agree: Barry Sherman will be tough to replace at Apotex
Described as a fierce competitor, aggressive in fighting Canadian patents and disqualifying them.
Valeant says it’s making progress halfway through planned turnaround
CEO warns transforming the embattled company is a multi-year process involving incremental steps.